Company news

Allogene Therapeutics, Inc. news in 2023

Allogene Therapeutics, Inc.'s news releases, calls and decks from 2023, newest first.

View company

Allogene Therapeutics Presents Comprehensive Safety Data of Proprietary Lymphodepletion Agent ALLO-647 at the 65th Annual Meeting of the American Society of Hematology

December 8, 2023

Allogene Therapeutics Announces Participation in December Investor Conference

November 30, 2023

Allogene Therapeutics Presents Preclinical Data on Next Generation Cloak™ and Dagger™ Technologies at the Society for Immunotherapy of Cancer Annual Meeting

November 2, 2023

Allogene Therapeutics Presents Preclinical Data on a Novel Allogeneic CAR T Product Candidate Targeting Claudin18.2 at the Society for Immunotherapy of Cancer Annual Meeting

November 2, 2023

Allogene Therapeutics Reports Third Quarter 2023 Financial Results and Business Update

November 1, 2023

Allogene Therapeutics Announces Poster Presentations at the 65th Annual Meeting of the American Society of Hematology

November 1, 2023

Allogene Therapeutics to Report Third Quarter 2023 Financial Results on November 2, 2023

October 25, 2023

Allogene Therapeutics Appoints Geoffrey Parker as Chief Financial Officer

October 15, 2023

Allogene Therapeutics Announces Three Poster Presentations from its Next Generation AlloCAR T™ Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

September 26, 2023

Allogene Therapeutics Announces Participation in September Investor Conference

September 4, 2023

Allogene Therapeutics Appoints Earl Douglas as General Counsel

August 13, 2023

Allogene Therapeutics Reports Second Quarter 2023 Financial Results and Business Update

August 1, 2023

Allogene Therapeutics to Report Second Quarter 2023 Financial Results on August 2, 2023

July 25, 2023

Allogene Therapeutics Provides Additional ALLO-501/501A Phase 1 Data in an Oral Presentation at the International Conference on Malignant Lymphoma (ICML) Lugano

June 14, 2023

Allogene Therapeutics Announces Departure of Chief Financial Officer

June 13, 2023

Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-501/501A in Large B Cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) Lugano

June 8, 2023

Allogene Therapeutics Presents Updated ALLO-501/501A Phase 1 Data in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting

June 2, 2023

Allogene Therapeutics Announces Participation in Three Upcoming Investor Conferences

May 23, 2023

Allogene Therapeutics Announces Encore Presentation of Phase 1 Data from the ALLO-501/501A Trials in Large B Cell Lymphoma at the European Hematology Association (EHA) Hybrid Congress

May 10, 2023

Allogene Therapeutics Reports First Quarter 2023 Financial Results and Business Update

May 2, 2023

Allogene Therapeutics Announces Presentation of Phase 1 Data from the ALLO-501/501A Trials in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting

April 25, 2023

Allogene Therapeutics to Report First Quarter 2023 Financial Results on May 3, 2023

April 24, 2023

Allogene Therapeutics Appoints Timothy Moore as Chief Technical Officer

April 19, 2023

Allogene Therapeutics Presents Interim Phase 1 Data on ALLO-316 in Renal Cell Carcinoma at the American Association of Cancer Research (AACR) Annual Meeting

April 16, 2023

Allogene Therapeutics Announces Participation in Four Upcoming Investor Conferences

April 12, 2023

Allogene Therapeutics Publishes 2022 Annual Environmental, Social and Governance (ESG) Report

March 29, 2023

Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-316 at the American Association of Cancer Research (AACR) Annual Meeting

March 13, 2023

Allogene Therapeutics Announces Participation in Two Upcoming Investor Conferences

March 1, 2023

Allogene Therapeutics Announces Publication of Industry-Advancing Case Study on Chromosomal Rearrangement in Molecular Therapy

February 28, 2023

Allogene Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

February 27, 2023

Allogene Therapeutics to Report Fourth Quarter and Year-End 2022 Financial Results on February 28, 2023

February 20, 2023

Allogene Therapeutics Presents Data on Dagger™, a Next Generation AlloCAR T™ Platform Technology

January 31, 2023

Allogene Therapeutics Publishes Preclinical Data in Clinical Cancer Research Supporting DLL3 as a Potential AlloCAR T™ Target for Small Cell Lung Cancer

January 24, 2023

Allogene Therapeutics Announces Publication in Nature Medicine of Data from its Phase 1 UNIVERSAL Study of ALLO-715 for the Treatment of Relapsed/Refractory Multiple Myeloma

January 23, 2023

Allogene Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

January 3, 2023

Allogene Appoints Zachary J. Roberts, M.D., Ph.D. as Executive Vice President of Research & Development

January 2, 2023

Calls in 2023

Decks in 2023